Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Imatinib mesylate for steroid-refractory chronic cutaneous graft-versus-host disease after allogeneic bone marrow transplantation
IRCT201302261030N12Phase 2Completed
- Sponsor
- Hematology, Oncology and Stem Cell Transplantation Research Center
- Start
- Aug 2012
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of imatinib in chronic graft-versus-host disease (cGVHD) and graft-versus-host disease (GVHD), sponsored by Hematology, Oncology and Stem Cell Transplantation Research Center. Started Aug 2012; status: completed.
02
Drugs
03
Conditions
chronic graft-versus-host disease (cGVHD)graft-versus-host disease (GVHD)
Beyond the preview
Go deeper on IRCT201302261030N12.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on IRCT201302261030N12.